Literature DB >> 7510748

Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.

L A Cavacini1, C L Emes, J Power, M Duval, M R Posner.   

Abstract

F(ab) and F(ab')2 fragments of the human mAb, F105, were compared to intact IgG1 for binding to the CD4 binding site of HIV-1/gp120 on the surface of infected cells and viral neutralization. F105 IgG1 and F(ab')2 bound to IIIB, MN, and RF infected cells and neutralized these strains in an identical fashion, whereas strain-specific differences were observed in F(ab) activity. Although F105 F(ab) bound with equivalent affinity to IIIB-infected cells, there was a 4- to 10-fold decrease in the neutralization of IIIB by monovalent F(ab) compared to the bivalent molecules. F105 F(ab) demonstrated both diminished binding and neutralization of the MN strain and failed to bind or neutralize the RF strain. When cooperativity of V3 loop antibody (V3ab) with F105 IgG and fragments was examined, the binding of F105 IgG and F(ab')2 to IIIB-, MN-, or RF-infected cells was modestly enhanced by V3ab; viral neutralization was substantially enhanced by the combination of V3ab and F105 IgG and F(ab')2. The combination of F105 F(ab) with V3ab also resulted in significant cooperative neutralization of IIIB and MN, but the lack of F105 F(ab) binding and neutralization of RF was unaltered by V3ab. These results suggest that bivalent interaction may be important in binding and neutralization of virus, and support the notion that this interaction may depend on conformational changes in oligomeric gp120 on intact virions and cell surface rather than on affinity or steric effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510748

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  HIV: Antibodies with a split personality.

Authors:  Andreas Plückthun
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

3.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

4.  Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?

Authors:  O Pritsch; G Hudry-Clergeon; M Buckle; Y Petillot; J P Bouvet; J Gagnon; G Dighiero
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

5.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

6.  Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.

Authors:  J S McDougal; M S Kennedy; S L Orloff; J K Nicholson; T J Spira
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.

Authors:  Susanne Wolbank; Renate Kunert; Gabriela Stiegler; Hermann Katinger
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 8.  The role of Fc receptors in HIV prevention and therapy.

Authors:  Austin W Boesch; Eric P Brown; Margaret E Ackerman
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

9.  Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance.

Authors:  D J Schofield; N J Dimmock
Journal:  J Virol Methods       Date:  1996-10       Impact factor: 2.014

10.  Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.

Authors:  Edurne Rujas; Iga Kucharska; Yong Zi Tan; Samir Benlekbir; Hong Cui; Tiantian Zhao; Gregory A Wasney; Patrick Budylowski; Furkan Guvenc; Jocelyn C Newton; Taylor Sicard; Anthony Semesi; Krithika Muthuraman; Amy Nouanesengsy; Clare Burn Aschner; Katherine Prieto; Stephanie A Bueler; Sawsan Youssef; Sindy Liao-Chan; Jacob Glanville; Natasha Christie-Holmes; Samira Mubareka; Scott D Gray-Owen; John L Rubinstein; Bebhinn Treanor; Jean-Philippe Julien
Journal:  Nat Commun       Date:  2021-06-16       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.